Exploring mechanisms of acquired resistance to HER2 (human epidermal growth factor receptor 2)-targeted therapies in breast cancer
- PMID: 25109964
- DOI: 10.1042/BST20140109
Exploring mechanisms of acquired resistance to HER2 (human epidermal growth factor receptor 2)-targeted therapies in breast cancer
Abstract
HER2 (human epidermal growth factor receptor 2)-targeted therapy in breast cancer is one of the earliest and arguably most successful examples of the modern class of targeted drugs. Initially identified in the 1980s, the observation that HER2 acts as an independent predictor of poor prognosis in the 20% of breast cancer cases carrying a gene amplification or protein overexpression cemented its place at the forefront of research in this field. The outlook for patients with HER2-positive breast cancer has been revolutionized by the introduction of HER2-targeted agents, such as trastuzumab and lapatinib, yet resistance is frequently encountered and multiple different resistance mechanisms have been identified. We have explored resistance to a novel pan-HER inhibitor, AZD8931, and we examine mechanisms of resistance common to trastuzumab, lapatinib and AZD8931, and discuss the current problems associated with translating the wealth of pre-clinical data into clinical benefit.
Similar articles
-
Efficacy of HER2-targeted therapy in metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors.Breast. 2013 Feb;22(1):1-12. doi: 10.1016/j.breast.2012.09.008. Epub 2012 Oct 16. Breast. 2013. PMID: 23084121 Review.
-
HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.Breast Cancer Res Treat. 2011 Nov;130(1):29-40. doi: 10.1007/s10549-010-1281-5. Epub 2010 Dec 9. Breast Cancer Res Treat. 2011. PMID: 21153051
-
Inhibitor of Apoptosis (IAP) survivin is indispensable for survival of HER2 gene-amplified breast cancer cells with primary resistance to HER1/2-targeted therapies.Biochem Biophys Res Commun. 2011 Apr 8;407(2):412-9. doi: 10.1016/j.bbrc.2011.03.039. Epub 2011 Mar 21. Biochem Biophys Res Commun. 2011. PMID: 21402055
-
Targeting HER2 for the treatment of breast cancer.Annu Rev Med. 2015;66:111-28. doi: 10.1146/annurev-med-042513-015127. Annu Rev Med. 2015. PMID: 25587647 Review.
-
Blockade of the HER family of receptors in the treatment of HER2-positive metastatic breast cancer.Clin Breast Cancer. 2012 Feb;12(1):19-29. doi: 10.1016/j.clbc.2011.07.001. Epub 2011 Sep 8. Clin Breast Cancer. 2012. PMID: 21903480 Review.
Cited by
-
The Under-Appreciated Promiscuity of the Epidermal Growth Factor Receptor Family.Front Cell Dev Biol. 2016 Aug 22;4:88. doi: 10.3389/fcell.2016.00088. eCollection 2016. Front Cell Dev Biol. 2016. PMID: 27597943 Free PMC article. Review.
-
Use of a genetically engineered mouse model as a preclinical tool for HER2 breast cancer.Dis Model Mech. 2016 Feb;9(2):131-40. doi: 10.1242/dmm.023143. Epub 2015 Dec 31. Dis Model Mech. 2016. PMID: 26721874 Free PMC article.
-
Identification of novel pathways linking epithelial-to-mesenchymal transition with resistance to HER2-targeted therapy.Oncotarget. 2016 Mar 8;7(10):11539-52. doi: 10.18632/oncotarget.7317. Oncotarget. 2016. PMID: 26883193 Free PMC article.
-
Integrative analysis of multi-platform reverse-phase protein array data for the pharmacodynamic assessment of response to targeted therapies.Sci Rep. 2020 Dec 15;10(1):21985. doi: 10.1038/s41598-020-77335-0. Sci Rep. 2020. PMID: 33319783 Free PMC article.
-
Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors.Nat Med. 2018 Feb;24(2):203-212. doi: 10.1038/nm.4472. Epub 2018 Jan 15. Nat Med. 2018. PMID: 29334371
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous
